The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort

Abstract Background Cerebrospinal fluid (CSF) analysis for detecting amyloid positivity may be as reliable as positron emission tomography (PET). We evaluated the performance of the amyloid beta (Aβ)42/40 ratio for predicting amyloid positivity by PET, compared with Aβ42 alone, and phosphorylated ta...

Full description

Bibliographic Details
Main Authors: Michaela Amft, Marion Ortner, Udo Eichenlaub, Oliver Goldhardt, Janine Diehl-Schmid, Dennis M. Hedderich, Igor Yakushev, Timo Grimmer
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s Disease
Cerebrospinal Fluid
Biomarkers
Positron Emission Tomography
Aβ42/40 Ratio
Online Access:https://doi.org/10.1186/s13195-022-01003-w

Internet

https://doi.org/10.1186/s13195-022-01003-w

Similar Items